John P. Thomas

John P. Thomas

Auto-generated profile, based on publicly available information

John P. Thomas

Division of Digestive Diseases Department of Metabolism Digestion and Reproduction Imperial College London London UK

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2026 in JCC Plus
Verified
Journal Article
Open access
PDF file
JTJohn P. Thomas
John P. Thomas
ASAamir Saifuddin
Aamir Saifuddin
SMSadek Malas
Sadek Malas
MMMeztli Matadamas-Guzman
Meztli Matadamas-Guzman
CPCristina Di Poto
Cristina Di Poto
NPNick Powell
Nick Powell
Background: Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and psychosocial factors. However, robust biomarkers to predict individual treatment response are currently lacking. Aims: The Therapy Personalisation using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) study aims to address this critical unmet need by identifying predictors that differentiate responders from non‐responders to advanced therapies in ulcerative colitis (UC) using an integrated multiomics approach. Methods: The THAMES‐IBD study is a multicentre, prospective observational cohort study recruiting adults with active UC initiating or switching advanced therapies, alongside patients with inactive UC and non‐IBD controls. Multimodal samples will be collected from recruited participants prior to treatment initiation, including stool (metagenomics and metabolomics), blood (transcriptomics, proteomics and metabolomics) and mucosal biopsies (transcriptomics). Longitudinal blood and stool samples, as well as clinical, demographic, dietary and comprehensive psychosocial data, will be collected at baseline and at 8–14 weeks and 28–32 weeks after commencing a new advanced therapy. Treatment outcomes will be pragmatically defined based on validated patient‐reported outcome (PRO‐2) scores and biochemical measures. Multiomics integration will be performed using complementary unsupervised and supervised approaches. Predictive models will undergo internal cross‐validation and, where feasible, external validation in independent cohorts. Conclusion: Through deep multimodal phenotyping of patients with UC, the THAMES‐IBD study seeks to identify biological mechanisms associated with therapeutic response and resistance. These insights have the potential to inform the development of novel predictive biomarkers to guide precision medicine strategies, minimise ineffective treatment cycling and ultimately improve outcomes for patients with IBD.

4 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYufan Liu
Yufan Liu
JTJohn P. Thomas
John P. Thomas
BBBalazs Bohar
Balazs Bohar
DMDezső Módos
Dezső Módos
NPNick Powell
Nick Powell
TKTamás Korcsmáros
Tamás Korcsmáros
Ulcerative colitis (UC) is a genetically heterogeneous disease causing chronic intestinal inflammation. Genome-wide association studies have linked numerous non-coding single nucleotide polymorphisms (SNPs) to UC, yet how these variants relate to intestinal epithelial function and clinical outcomes remains largely unknown. To address this, we aimed to reconstruct patient-specific epithelial signalling and regulatory networks perturbed by non-coding SNPs and to dissect patient heterogeneity in a large UC phase 3 trial. We analysed genotype data from 452 participants in the etrolizumab phase 3 HICKORY cohort using the integrated SNP network platform (iSNP) to map the downstream effects of non-coding SNPs and identify transcription factors (TFs) they perturb in each patient. TFs were filtered to retain those with differential regulatory activity in UC epithelial cells, patients were stratified by these TF profiles, and clusters were correlated with etrolizumab outcomes. We identified 14 SNP-propagated TFs with differential epithelial regulatory activity. Unsupervised clustering stratified patients into subgroups differing in disease severity and treatment response: two clusters had the highest severity and lowest remission and response rates, whereas two others had the best outcomes. iSNP-based clustering improved endoscopic healing prediction (p = 0.03), with trends for clinical response and histological endoscopic mucosal improvement. This systems genomics framework links patient-specific non-coding SNPs to epithelial signalling and regulatory networks in UC and captures clinically meaningful heterogeneity associated with treatment outcomes. It supports genetics-informed precision medicine and improved clinical trial design in inflammatory bowel disease and beyond.